Nasitrim Duoeffect (Xylometazoline Hydrochloride, Ipratropium Bromide)

Xylometazoline Hydrochloride/Ipratropium Bromide, the active ingredients in Nasitrim Duoeffect, are an alpha‑adrenergic agonist and an antimuscarinic presented as a nasal spray for intranasal use. They work together to relieve nasal congestion caused by allergic rhinitis, the common cold, and other upper‑respiratory irritations.

GNH USA supplies Nasitrim Duoeffect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasitrim Duoeffect combines two agents that act on nasal congestion pathways, providing relief in several common conditions.

Allergic rhinitis: reduces nasal swelling and secretions, improving airflow. Common cold: alleviates congestion and runny nose associated with viral upper‑respiratory infection. Upper respiratory tract irritation: diminishes mucosal edema and excessive secretions, easing breathing discomfort.

Nasitrim Duoeffect may cause local and systemic reactions, most of which are mild and transient.

Common Side Effects: - Nasal burning or stinging sensation. - Mild headache. - Dryness of the nasal mucosa. - Sneezing. - Unpleasant taste. - Transient epistaxis (nosebleed).

Serious or Rare Side Effects: - Severe nasal irritation or ulceration. - Persistent hypertension. - Cardiac arrhythmia. - Allergic reactions such as rash, pruritus, or angioedema. - Vision changes. - Severe dizziness or fainting.

Before using Nasitrim Duoeffect, consider the following safety measures.

Avoid use in patients with known hypersensitivity to either component. Monitor blood pressure in individuals with cardiovascular disease. Use cautiously in patients with glaucoma or urinary retention. Do not exceed recommended duration to avoid rebound congestion. Pregnant or breastfeeding individuals should consult a healthcare professional. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Nasitrim Duoeffect can interact with other medications that affect cardiovascular or anticholinergic pathways.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (risk of hypertensive crisis). - Other nasal decongestants (risk of excessive vasoconstriction). - Systemic antihypertensives (may blunt blood pressure control).

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (additive drying effects). - Beta‑blockers (potential additive cardiovascular effects). - Certain antidepressants (possible additive nasal irritation).